BBIO insider transaction filings
BridgeBio Pharma, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen BBIO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 1,900 @ $81.15 · Sale (S): 17,279 @ $82.21 · Sale (S): 14,602 @ $82.99 · Sale (S): 1,199 @ $83.77 · Sale (S): 8,100 @ $83.86 · Sale (S): 1,800 @ $84.69 · +1 more | EDGAR |
| 2026-08-18 | 4 | Apuli Maricel — Chief Accounting Officer | Tax withholding (F): 4,714 @ $79.86 | EDGAR |
| 2026-08-18 | 4 | Kumar Neil — Chief Executive Officer, Director | Option exercise (M): 33,544 · Option exercise (M): 19,599 · Option exercise (M): 11,554 · Option exercise (M): 6,520 · Tax withholding (F): 36,237 @ $79.86 · Option exercise (M): 33,544 (derivative) @ $0 · +3 more | EDGAR |
| 2026-08-18 | 4 | Trimarchi Thomas — President and CFO | Tax withholding (F): 22,781 @ $79.86 | EDGAR |
| 2026-08-03 | 4 | Apuli Maricel — Chief Accounting Officer | Sale (S): 2,000 @ $80.06 | EDGAR |
| 2026-07-13 | 4 | Ellis Andrea — Director | Option exercise (M): 17,167 @ $16.75 · Sale (S): 17,167 @ $84 · Option exercise (M): 17,167 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Cook Jennifer E. — Director | Option exercise (M): 19,000 @ $8.45 · Option exercise (M): 112,422 @ $29 · Option exercise (M): 17,167 @ $16.75 · Sale (S): 36,167 @ $84 · Sale (S): 112,422 @ $90 · Option exercise (M): 19,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-24 | 4 | Cook Jennifer E. — Director | Grant/award (A): 3,990 @ $0 · Sale (S): 2,196 @ $68.57 · Option exercise (M): 20,000 @ $8.45 · Option exercise (M): 17,167 @ $16.75 · Sale (S): 37,167 @ $70 · Grant/award (A): 5,277 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-24 | 4 | Valantine Hannah — Director | Grant/award (A): 3,990 @ $0 · Option exercise (M): 2,808 @ $41.73 · Sale (S): 2,808 @ $68 · Sale (S): 2,196 @ $68.57 · Grant/award (A): 5,277 (derivative) @ $0 · Option exercise (M): 2,808 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Ellis Andrea — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Lo Andrew — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Dachille Douglas A. — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Satvat Ali J. — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | AGUIAR ERIC — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | MCCORMICK FRANK — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | MOMTAZEE JAMES C — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | HOMCY CHARLES J — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | DANIELS RONALD J — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Hassan Fred — Director | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | HOMCY CHARLES J — Director | Tax withholding (F): 788 @ $66.27 | EDGAR |
| 2026-06-17 | 4 | Cook Jennifer E. — Director | Option exercise (M): 65,921 @ $8.45 · Option exercise (M): 17,167 @ $16.75 · Sale (S): 88,737 @ $66.62 · Sale (S): 1,503 @ $67.14 · Option exercise (M): 65,921 (derivative) @ $0 · Option exercise (M): 17,167 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 2,200 @ $65.72 · Sale (S): 1,429 @ $66.72 · Sale (S): 15,921 @ $67.74 · Sale (S): 450 @ $68.27 · Sale (S): 2,200 @ $65.72 · Sale (S): 1,429 @ $66.72 · +8 more | EDGAR |
| 2026-05-26 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 2,256 @ $67.57 · Sale (S): 6,725 @ $68.30 · Sale (S): 5,072 @ $69.22 · Sale (S): 11,250 @ $70.48 · Sale (S): 800 @ $70.92 | EDGAR |
| 2026-05-19 | 4 | Trimarchi Thomas — President and CFO | Tax withholding (F): 22,781 @ $66.13 · Sale (S): 10,456 @ $64.82 · Sale (S): 3,195 @ $65.95 | EDGAR |
| 2026-05-19 | 4 | Apuli Maricel — Chief Accounting Officer | Tax withholding (F): 4,714 @ $66.13 | EDGAR |
| 2026-05-19 | 4 | Kumar Neil — Chief Executive Officer, Director | Option exercise (M): 33,544 · Option exercise (M): 19,599 · Option exercise (M): 11,553 · Option exercise (M): 6,519 · Tax withholding (F): 36,236 @ $66.13 · Option exercise (M): 33,544 (derivative) @ $0 · +3 more | EDGAR |
| 2026-05-19 | 4 | Scott Randal W. — Director | Option exercise (M): 10,000 @ $16.75 · Sale (S): 6,200 @ $66.69 · Sale (S): 2,088 @ $67.53 · Sale (S): 1,512 @ $68.23 · Sale (S): 200 @ $69.12 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 11,217 @ $67.50 · Sale (S): 8,333 @ $68.38 · Sale (S): 450 @ $69.09 · Sale (S): 11,217 @ $67.49 · Sale (S): 8,334 @ $68.38 · Sale (S): 449 @ $69.09 · +6 more | EDGAR |
| 2026-05-04 | 4 | Apuli Maricel — Chief Accounting Officer | Sale (S): 2,000 @ $71.58 | EDGAR |
| 2026-04-13 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 7,200 @ $73.64 · Sale (S): 5,300 @ $74.60 · Sale (S): 7,500 @ $75.55 · Sale (S): 7,072 @ $73.64 · Sale (S): 5,128 @ $74.57 · Sale (S): 7,800 @ $75.53 · +2 more | EDGAR |
| 2026-03-20 | 4 | Trimarchi Thomas — President and CFO | Grant/award (A): 59,041 @ $0 | EDGAR |
| 2026-03-20 | 4 | Apuli Maricel — Chief Accounting Officer | Grant/award (A): 14,170 @ $0 | EDGAR |
| 2026-03-19 | 4 | Kumar Neil — Chief Executive Officer, Director | Grant/award (A): 40,570 (derivative) @ $0 · Grant/award (A): 104,313 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 14,337 @ $68.48 · Sale (S): 5,363 @ $69.32 · Sale (S): 300 @ $70.15 · Sale (S): 13,885 @ $68.47 · Sale (S): 5,815 @ $69.29 · Sale (S): 300 @ $70.15 · +4 more | EDGAR |
| 2026-03-12 | 4 | Valantine Hannah — Director | Option exercise (M): 8,671 @ $27.36 · Sale (S): 8,671 @ $72 · Option exercise (M): 8,671 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Ellis Andrea — Director | Option exercise (M): 64,921 @ $8.45 · Sale (S): 64,921 @ $64.87 · Option exercise (M): 64,921 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Valantine Hannah — Director | Option exercise (M): 25,484 @ $48.45 · Sale (S): 14,584 @ $67.08 · Sale (S): 10,900 @ $67.84 · Option exercise (M): 25,484 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | Apuli Maricel — Chief Accounting Officer | Sale (S): 2,000 @ $66 | EDGAR |
| 2026-02-23 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 18,923 @ $71.03 · Sale (S): 8,528 @ $72.08 · Sale (S): 602 @ $72.80 | EDGAR |
| 2026-02-18 | 4 | Apuli Maricel — Chief Accounting Officer | Tax withholding (F): 4,349 @ $75.25 · Sale (S): 510 @ $74.31 | EDGAR |
| 2026-02-18 | 4 | Trimarchi Thomas — President and CFO | Tax withholding (F): 18,819 @ $75.25 · Sale (S): 13,400 @ $74.71 · Sale (S): 200 @ $75.38 | EDGAR |
| 2026-02-18 | 4 | Kumar Neil — Chief Executive Officer, Director | Option exercise (M): 33,544 · Option exercise (M): 19,600 · Option exercise (M): 11,554 · Tax withholding (F): 30,970 @ $75.25 · Option exercise (M): 33,544 (derivative) @ $0 · Option exercise (M): 19,600 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-18 | 4 | Scott Randal W. — Director | Option exercise (M): 10,000 @ $16.75 · Sale (S): 1,900 @ $74.34 · Sale (S): 4,793 @ $75.57 · Sale (S): 3,307 @ $75.93 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-02-12 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 14,201 @ $71.80 · Sale (S): 5,799 @ $72.28 · Sale (S): 14,040 @ $71.80 · Sale (S): 5,960 @ $72.27 · Sale (S): 7,806 @ $70.69 · Sale (S): 3,716 @ $71.44 · +6 more | EDGAR |
| 2026-01-12 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 11,515 @ $73.64 · Sale (S): 8,085 @ $74.38 · Sale (S): 400 @ $75.16 · Sale (S): 11,565 @ $73.65 · Sale (S): 8,135 @ $74.38 · Sale (S): 300 @ $75.20 · +8 more | EDGAR |
| 2025-12-16 | 4 | Trimarchi Thomas — President and CFO | Tax withholding (F): 13,826 @ $75.15 | EDGAR |
| 2025-12-16 | 4 | Apuli Maricel — Chief Accounting Officer | Tax withholding (F): 2,003 @ $75.15 | EDGAR |
| 2025-12-16 | 4 | Kumar Neil — Chief Executive Officer, Director | Option exercise (M): 60,975 · Tax withholding (F): 30,964 @ $75.15 · Sale (S): 28,311 @ $74.60 · Sale (S): 1,700 @ $75.24 · Option exercise (M): 60,975 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Apuli Maricel — Chief Accounting Officer | Sale (S): 2,000 @ $74.26 | EDGAR |
| 2025-12-08 | 4 | Kumar Neil — Chief Executive Officer, Director | Sale (S): 2,100 @ $73.16 · Sale (S): 12,192 @ $74.42 · Sale (S): 5,708 @ $74.80 · Sale (S): 12,517 @ $73.05 · Sale (S): 7,483 @ $73.76 · Sale (S): 2,100 @ $73.16 · +4 more | EDGAR |
Recent 8-K events — BridgeBio Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events | EDGAR |
| 2026-03-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BBIO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →